Fulcrum Therapeutics Q1 2024 Financial Results Call on May 13, 2024

May 06, 2024 -- Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker symbol FULC, is dedicated to developing small molecule therapies aimed at improving the lives of patients with genetically defined rare diseases. The company has announced that it will release its financial results for the first quarter of 2024 on Monday, May 13, 2024, before the U.S. financial markets open. In conjunction with the release, Fulcrum’s management team will host a conference call and webcast at 8:00 a.m. ET to discuss their financial performance and provide updates on recent corporate activities.

Interested individuals are invited to register for the conference call to receive dial-in details and a unique PIN necessary for accessing the call. Additionally, the company will offer an audio webcast of the call, which can be accessed through the Investor Relations section of Fulcrum Therapeutics' website. An archived replay of the webcast will be made available following the live event.

Fulcrum Therapeutics is focused on discovering and developing treatments for genetically defined rare diseases where there is a significant unmet medical need. The company’s two primary programs currently in clinical development are losmapimod and pociredir. Losmapimod is a small molecule being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Pociredir is designed to increase the expression of fetal hemoglobin and is in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies.

Fulcrum utilizes proprietary technology to discover drug targets capable of modulating gene expression, addressing the root cause of gene mis-expression. This innovative approach aims to provide effective treatments for patients suffering from rare genetic disorders. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!